This brochure offers an overview of the latest EU Drug Markets Report, from the EMCDDA and Europol. Published every three years, the report provides a state-of-the-art analysis of the illicit drug market, covering trends along the supply chain from production and trafficking to marketing, distribution and consumption. The report combines the EMCDDA’s drug monitoring and analytical capacity with Europol’s operational intelligence on trends in organised crime.
Today, the European Commission has proposed to subject the new psychoactive substance MDMB-CHMICA (sometimes referred to as ‘Black Mamba’) to control measures across the European Union.
This rapid communication provides an update on drug related hospital emergency presentations in Europe with a specific focus on the latest results for acute drug toxicity presentations to the European Drug Emergencies Network (Euro-DEN). This report is primarily based on presentations and discussions at a two-day meeting of the Euro-DEN Plus network in Lisbon on 7 and 8 April 2016. The meeting provided a platform for the presentation of new analyses from the Euro-DEN dataset, and further development and analyses of the Euro-DEN project were also discussed.
Data from hospital emergency departments show that every year in Europe thousands of individuals experience drug-related poisoning and other harms, requiring some kind of medical assistance.
Hepatitis C among drug users in Europe: epidemiology, treatment and prevention provides a timely contribution to raising awareness of the hepatitis C epidemic in Europe and the opportunities now opening up to tackle this problem decisively. A state-of-the-art review of the epidemiology of hepatitis C virus (HCV) infection in Europe and an overview of the way preventive measures are currently implemented in European countries set the scene.
Hepatitis C is an infectious disease of the liver caused by the blood-borne hepatitis C virus. In a new report published today on World Hepatitis Day, the EU drugs agency (EMCDDA) looks at new opportunities for the effective prevention and treatment of hepatitis C.
This publication presents the data and findings of the risk assessment on α-PVP (1-phenyl- 2-(1-pyrrolidinyl)-1-pentanone), carried out by the extended Scientific Committee of the EMCDDA on 18 November 2015. α-PVP is the eleventh new psychoactive substance to be risk assessed under the terms of Council Decision 2005/387/JHA. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 27 June 2016, the Council decided that α-PVP should be subject to control measures across the Member States.
Members of the European Parliament Committee on Civil Liberties, Justice and Home Affairs (LIBE) start a two-day visit to the EMCDDA today where they will hear presentations on the agency’s contribution to a more secure and a healthier Europe.
This report presents the key activities performed by the EMCDDA and Europol in 2015 and the results of the implementation of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances, including new psychoactive substances notified in 2015, Joint Reports produced, risk assessments conducted and public health-related alerts and advisories issued to the EU Early Warning System Network.
EMCDDA Director Alexis Goosdeel is in Berlin today where he is speaking at a public hearing at the German Parliament (Bundestag) on the issue of new psychoactive substances (NPS). The hearing is organised by the Bundestag Health Committee and chaired by Dr Edgar Franke (Member of the German Parliament).
In February 2016, the EMCDDA and Europol examined the available information on a new psychoactive substance methyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate, commonly known as MDMB-CHMICA, through a joint assessment. The two organisations concluded that sufficient information had been accumulated to merit the production of a Joint Report on MDMB-CHMICA as stipulated by Article 5.1 of the Council Decision.
These are the EMCDDA's final annual accounts for the financial year 2015.
The EU drugs agency (EMCDDA) is hosting a conference in Lisbon today marking the end of a 30-month technical cooperation project within the framework of the European Neighbourhood Policy (ENP).
In this issue: European Drug Report 2016 highlights | Return of MDMA | Rises in overdose deaths | Health responses to new psychoactive substances | Gold medal for EMCDDA | World hepatitis day | New EMCDDA products and services | 2016 EMCDDA scientific paper award
The fifth European drugs summer school — ‘Illicit drugs in Europe: demand, supply and public policies’ — opened today in Lisbon and will run until 8 July. The initiative, organised by ISCTE and the EMCDDA, is supported by NIDA.
The emergence of new psychoactive substances (NPS) over the last decade has posed a major challenge to drug policy. While the limited available data indicates that prevalence levels of NPS use are relatively low in the general European population, there are concerns around more problematic forms of use and harms in particular drug using populations. A number of public health concerns have arisen as a consequence of their use, although the real extent of these harms across Europe remains unknown.
While prevalence levels of NPS use remain low in the general European population, there are important concerns with more problematic forms of use and harms. This short report provides an overview of the current situation in terms of NPS use and harms across Europe and reviews the available health- and drug-related interventions in that area.
In its latest report, released today ahead of International day against drug abuse and illicit trafficking (26 June), the EMCDDA presents its first analysis of the health responses to NPS.
The General Report of Activities is an annual publication providing a detailed progress report of the EMCDDA’s activities over a 12-month period. It catalogues the Centre’s achievements in each area of its annual work programme. The report is a useful information source for all those seeking comprehensive information on the Centre and its work.
In September 2015, the EMCDDA and Europol examined the available information on a new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (acetylfentanyl), through a joint assessment. The two organisations concluded that sufficient information had been accumulated to merit the production of a Joint Report on acetylfentanyl as stipulated by Article 5.1 of the Council Decision.
The use of substitution drugs for the treatment of opioid dependence represents a key evidence-based response to heroin problems in Europe. However, the diversion of these medicines from their intended use in drug treatment to non-medical use and sale on illicit drug markets is a cause for concern. The use of diverted substances has been associated with fatal and non-fatal overdose and an increased incidence of opioid dependence.
Comorbidity of substance use and mental health disorders refers to the co-occurrence of a substance use disorder and another mental health disorder in the same individual. In Europe, the presence of psychiatric disorders associated with substance use disorders has become an important issue in drug policy and treatment provision. This is a result of the high prevalence of comorbidity, the complexity of treating it, and its association with poor treatment outcomes for those affected.
Psychosocial interventions are structured psychological or social interventions used to address substance-related problems. They can be used at different stages of drug treatment to identify the problem, treat it and assist with social reintegration. Psychosocial interventions are used to treat many different types of drug problems and behavioural addictions. This analysis explains what the main psychosocial interventions are and to whom they are provided.
The number and diversity of new psychoactive substances reported in Europe in recent years represents a major challenge for Europe’s policymakers. This analysis looks at countries’ legal responses to the new drugs phenomenon.
Transmitted through the sharing of needles, syringes and other injecting equipment, hepatitis C is the most common infectious disease among injecting drug users in Europe today.In this analysis, the EMCDDA looks at some of the positive advances in treating the disease, including a new generation of medicines.
This brochure provides an overview of the 2016 European Drug Report package and includes brief summaries of the four new additions to the Perspectives on drugs (PODs) series.
Three United Nations Conventions provide the international legal framework on drug control, instructing countries to limit drug supply and use to medical and scientific purposes. Yet, debate is increasing on the legalisation of drugs for non-medical purposes, particularly cannabis. Models under development for the legal supply of cannabis are described in this analysis, as well as some of the questions they raise.
Cocaine is Europe’s most commonly used illicit stimulant drug, with about 3.6 million adults (aged 15–64) estimated to have used it in the last year. It is the second most seized drug in Europe, after cannabis. Cocaine is trafficked to Europe from the producer countries of South America by both air and sea using a range of methods and routes. This analysis provides an insight into the European cocaine market, the trafficking routes used to bring it to Europe, and the different methods criminals employ to move their drugs.
The Trends and Developments report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as drug policy and responses. Together with the online Statistical Bulletin, Country Overviews and Perspectives on Drugs, it makes up the 2016 European Drug Report package.
Europe’s drug market remains resilient, says the EU drugs agency (EMCDDA) today as it launches in Lisbon its European Drug Report 2016: Trends and Developments,